Latest Period
Q1 2026
Security Snapshot
NEKTAR THERAPEUTICS - COMMON STOCK (NKTR) Institutional Ownership
CUSIP: 640268306
13F Institutional Holders and Ownership History from Q2 2025 to Q1 2026
Institutions Reporting
208
Shares (Excl. Options)
26,700,054
Price
$71.95
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / COMMON STOCK
- Symbol
- NKTR on Nasdaq
- All holders as of 31 Mar 2026
- Q1 2026
- Total 13F shares
- 26,700,054
- Total 13F value
- $1,919,389,645
- Portfolio coverage rank
- 0.01%
- Share change
- +9,032,246
- Value change
- +$690,438,367
- Number of holders
- 208
- Shares outstanding
- 28,687,922
- SEC-reported price per share
- $78.43
- Insider filing price
- $78.43
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
3 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Key facts
- NKTR - NEKTAR THERAPEUTICS - COMMON STOCK is tracked under CUSIP 640268306.
- 208 institutions reported positions in Q1 2026.
- 7 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 171 to 208 between Q4 2025 and Q1 2026.
- SEC-reported value moved from $731,897,039 to $1,919,389,645.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 208 institutions filings for Q1 2026.
Security key
640268306
Latest holder period
Q1 2026
13F holders
208
13D/G owners
7
CIK / CUSIP context first
Open Q1 2026 holders
NKTR full holder history
NEKTAR THERAPEUTICS SEC filings
NEKTAR THERAPEUTICS company facts
NEKTAR THERAPEUTICS insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 640268306:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
7
Security
NKTR
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| FMR LLC | 15% | +35% | $331,302,473 | +$97,502,292 | 4,303,188 | +42% | FMR LLC | 31 Mar 2026 |
| BIOTECHNOLOGY VALUE FUND L P | 7.4% | $32,978,662 | 1,276,595 | BVF PARTNERS L P/IL | 01 Jul 2025 | |||
| VANGUARD GROUP INC | 5% | +1.2% | $43,425,528 | +$3,316,543 | 1,027,089 | +8.3% | The Vanguard Group | 31 Dec 2025 |
| SUSQUEHANNA SECURITIES, LLC | 4% | -38% | $34,245,405 | -$18,006,925 | 809,967 | -34% | G1 Execution Services, LLC | 31 Dec 2025 |
| INTEGRATED CORE STRATEGIES (US) LLC | 3% | -48% | $32,489,559 | -$20,590,346 | 570,994 | -39% | Millennium Management LLC | 30 Sep 2025 |
| Nantahala Capital Management, LLC | 2.2% | -59% | $23,813,902 | -$16,571,499 | 418,522 | -41% | Nantahala Capital Management, LLC | 30 Sep 2025 |
| BlackRock, Inc. | 1.6% | $5,245,655 | 203,017 | BlackRock, Inc. | 30 Jun 2025 |
As of 31 Mar 2026, 208 institutional investors reported holding 26,700,054 shares of NEKTAR THERAPEUTICS - COMMON STOCK (NKTR). This represents 93% of the company’s total 28,687,922 outstanding shares.
13F concentration
Top 25 institutional shareholders
Largest 13F positions for this security by reported shares and value.
Top holder share
68%
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| FMR LLC | 15% | 4,303,188 | +4155% | 0.02% | $309,614,403 |
| BVF INC/IL | 8.9% | 2,559,595 | +64% | 5.9% | $184,162,860 |
| Two Seas Capital LP | 6.8% | 1,959,178 | +163% | 6.5% | $140,962,857 |
| VANGUARD CAPITAL MANAGEMENT LLC | 4.2% | 1,197,055 | 0% | 0% | $86,128,107 |
| TWO SIGMA INVESTMENTS, LP | 3.2% | 930,741 | +97% | 0.06% | $66,966,815 |
| Prosight Management, LP | 2.6% | 735,000 | +33% | 8.7% | $52,883,250 |
| BlackRock, Inc. | 2.4% | 692,650 | +7.3% | 0% | $49,836,168 |
| MORGAN STANLEY | 2.3% | 659,387 | +16% | 0% | $47,442,895 |
| ARMISTICE CAPITAL, LLC | 2% | 578,000 | -3% | 1.4% | $41,587,100 |
| Invesco Ltd. | 2% | 567,458 | +21% | 0.01% | $40,828,603 |
| CITADEL ADVISORS LLC | 1.8% | 513,531 | +66% | 0.03% | $36,948,555 |
| Sofinnova Investments, Inc. | 1.8% | 509,546 | +16% | 1.8% | $36,661,835 |
| Woodline Partners LP | 1.4% | 415,335 | +299% | 0.11% | $29,883,353 |
| LORD, ABBETT & CO. LLC | 1.4% | 405,080 | 0.1% | $29,146,000 | |
| MILLENNIUM MANAGEMENT LLC | 1.4% | 404,277 | -11% | 0.02% | $29,087,730 |
| EMERALD ADVISERS, LLC | 1.4% | 394,604 | +2.7% | 0.9% | $28,391,758 |
| Qube Research & Technologies Ltd | 1.4% | 390,675 | +21% | 0.04% | $28,109,066 |
| GEODE CAPITAL MANAGEMENT, LLC | 1.2% | 346,795 | +36% | 0% | $24,961,900 |
| UBS Group AG | 1.1% | 320,172 | +11% | 0% | $23,036,375 |
| GREAT POINT PARTNERS LLC | 1.1% | 316,453 | +50% | 5.6% | $22,768,793 |
| Vestal Point Capital, LP | 0.99% | 285,000 | 0.57% | $20,505,750 | |
| 22NW, LP | 0.98% | 281,115 | -15% | 16% | $20,226,224 |
| PRIMECAP MANAGEMENT CO/CA/ | 0.97% | 279,150 | -0.36% | 0.02% | $20,084,842 |
| ORBIMED ADVISORS LLC | 0.96% | 275,000 | 0.45% | $19,786,250 | |
| GILDER GAGNON HOWE & CO LLC | 0.95% | 271,758 | +30% | 0.23% | $19,552,988 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
4
Latest
Q1 2026
Rows shown
1-4 of 4
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 26,700,054 | $1,919,389,645 | +$690,438,367 | $71.95 | 208 |
| 2025 Q4 | 17,311,424 | $731,897,039 | +$83,234,784 | $42.28 | 171 |
| 2025 Q3 | 14,405,809 | $819,769,158 | +$416,306,829 | $56.90 | 143 |
| 2025 Q2 | 7,657,053 | $197,846,106 | +$197,839,388 | $25.84 | 100 |